Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Cepheid and bioMerieux enter into strategic agreements to develop and market sepsis, MRSA products
February 14th, 2007
Cepheid (CPHD) and bioMerieux (BIM) announced that they have entered into a strategic relationship wherein both companies will use the best of their respective technologies and commercial strengths towards the development and commercialization of an innovative line of sepsis test products on the GeneXpert platform. Both companies will jointly develop the products, Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive worldwide basis. The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. Cepheid will continue to complete development,...
Source: Medical Patent Law Weekly (2007-02-14)
|
